BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 3, 2008
View Archived Issues
siRNAs targeting PCSK9 reduce cholesterol in animals
Read More
Development of cannabinoid CB1 ligands for brain imaging described
Read More
Novel dual HER1/HER2 inhibitor shows antitumor activity in vivo
Read More
Novel spirofuran potassium channel openers designed for urinary incontinence
Read More
Novel alpha7 neuronal nicotinic receptor agonists synthesized at Abbott
Read More
New agents for treating obesity and nutritional disorders presented in recent patents
Read More
GPR88 identified as a potential target in psychiatric disorders
Read More
Novel JAK-3 inhibitor active as immunosuppressant in trachea transplanted rats
Read More
Clinical benefits and safety of novel antiplatelet agent SCH-530348 disclosed at the ESC congress
Read More
GSK withdraws European MAA for Quintanrix vaccine
Read More
FDA notifies Introgen that Advexin BLA not sufficiently complete to file
Read More
FDA accepts Alpharma's Embeda capsule NDA filing
Read More
GlaxoSmithKline returns Entereg rights to Adolor for opioid bowel dysfunction
Read More
Recent Vertex patent discloses new agents for AD and other neurological disorders
Read More
Idera receives milestone payment under asthma and allergy collaboration
Read More
Recent Boehringer Ingelheim patent describes novel analgesic agents
Read More
Olanzapine long-acting injection maintains treatment benefit for up to six months
Read More
Targanta presents top-line results from oritavancin phase II SIMPLIFI trial
Read More
Roche pays USD 15 million milestone to InterMune for development of HCV protease inhibitor
Read More
Pain Therapeutics receives USD 20,000,000 in milestone payments from King Pharmaceuticals
Read More
Vimpat approved in the E.U. for partial-onset seizures
Read More
HGS reports initial top-line results from phase II HGS-ETR1 trial
Read More
Intercell reports favorable six months follow-up results from phase II HCV trial
Read More